Cypress Capital Management (Wyoming)’s Ligand Pharmaceuticals LGND Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24	Closed	-$4K	–	354
2018 Q3	$4K	Hold	24	–	–	﹤0.01%	309
2018 Q2	$3K	Hold	24	–	–	﹤0.01%	306
2018 Q1	$2K	Hold	24	–	–	﹤0.01%	293
2017 Q4	$2K	Hold	24	–	–	﹤0.01%	299
2017 Q3	$2K	Hold	24	–	–	﹤0.01%	259
2017 Q2	$1.82K	Hold	24	–	–	﹤0.01%	252
2017 Q1	$1.59K	Sell	24 -2,244	-99%	-$148K	﹤0.01%	257
2016 Q4	$145K	Buy	2,268 +1,867	+466%	+$118K	0.15%	79
2016 Q3	$25.5K	Buy	+401	New	+$29.4K	0.03%	147
2016 Q2	–	Sell	-425	Closed	-$28.4K	–	241
2016 Q1	$28.4K	Buy	425 +185	+77%	+$11.2K	0.04%	129
2015 Q4	$16.3K	Hold	240	–	–	0.02%	164
2015 Q3	$12.8K	Buy	+240	New	+$14.6K	0.02%	171

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s LGND Position: Q4 2018 in Review

Cypress Capital Management (Wyoming) sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 24 shares — an estimated $4K sold.

Cypress Capital Management (Wyoming) first reported a position in LGND in Q3 2015 and held it in 12 quarters. The position peaked at $145K in Q4 2016. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Cypress Capital Management (Wyoming) reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Cypress Capital Management (Wyoming) sold 24 Ligand Pharmaceuticals shares in Q4 2018, an estimated $4K.
Cypress Capital Management (Wyoming) first reported a position in Ligand Pharmaceuticals in Q3 2015 and held it in 12 quarters.
Cypress Capital Management (Wyoming)'s Ligand Pharmaceuticals position peaked at $145K in Q4 2016.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q4 2018, filed 5 Feb 2019.